Open Trials at Pacific Cancer Care

Pacific Cancer Care is driven by a vision to be the leader for the treatment of cancer in the Monterey County. Our clinicians and investigators identify and conduct Phase I-IV treatment options that are new and innovative, and that will positively impact our patients. Below is a list of clinical trials currently available at Pacific Cancer Care.
For more information regarding clinical trial opportunities, please contact Monica Castillo, Clinical Research Manager, at mocastillo@pacificcancercare.com or call her at (831) 375-4105 ext. 1077

Breast Cancer
NCT #03523585
Destiny: A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1

Gastric or Gastroesophageal Junction (GEJ)
NCT # 03615326
Keynote-811: A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants with HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric or Gastroesophageal Junction (GEJ)
NCT #03653507
Glow: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Hematologic Malignancies
NCT #03598608
MK4280-003: A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab in Participants with Hematologic Malignancies

High-Risk Multiple Myeloma
NCT #03104270
CA204-187: A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone among high risk Relapsed/Refractory Multiple Myeloma Patients

Multiple Myeloma
NCT #03110822
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients

Non-Hodgkin’s Lymphomas
NCT #03893682
Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin’s Lymphomas

Non-Small Cell Lung Cancer
NCT #03425643
KEYNOTE-671: A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer
NCT #03515837
KEYNOTE-789: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants

Prostate Cancer
NCT # 02152631
JPCM: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer

Blood Cancer Research Partnership with Dana-Farber Cancer Institute

High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
NCT #03236428
Pilot Study of the CD38 Antibody Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma